The last major legal standoff for a Humira biosimilar has ended, as AbbVie and Boehringer Ingelheim announced this week a settlement of patent litigation over the U.S. entry date. Boehringer can begin selling its copycat of the world’s best-selling drug on July 1, 2023, paying royalties to AbbVie for the U.S. license, according to the settlement. Eight companies have now settled with AbbVie over Humira biosimilars. While Humira competition started this year in Europe, the deals reached in the U.S. give the giant biotech more than three years of stateside exclusivity, staving off all entries until 2023. Learn More